Literature DB >> 23388617

Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics.

Cayetano Gonzalez1.   

Abstract

For decades, lower-model organisms such as Drosophila melanogaster have often provided the first glimpse into the mechanism of action of human cancer-related proteins, thus making a substantial contribution to elucidating the molecular basis of the disease. More recently, D. melanogaster strains that are engineered to recapitulate key aspects of specific types of human cancer have been paving the way for the future role of this 'workhorse' of biomedical research, helping to further investigate the process of malignancy, and serving as platforms for therapeutic drug discovery.

Entities:  

Mesh:

Year:  2013        PMID: 23388617     DOI: 10.1038/nrc3461

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  166 in total

Review 1.  Polo-like kinases: conservation and divergence in their functions and regulation.

Authors:  Vincent Archambault; David M Glover
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04       Impact factor: 94.444

2.  A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.

Authors:  Byung Hak Kim; Chang-Hong Yin; Qianxu Guo; Erika A Bach; Haeryun Lee; Claudio Sandoval; Somasundaram Jayabose; Agnieszka Ulaczyk-Lesanko; Dennis G Hall; Gyeong-Hun Baeg
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 3.  Lessons from 60 years of pharmaceutical innovation.

Authors:  Bernard Munos
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

4.  Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster.

Authors:  Emmanuel Caussinus; Cayetano Gonzalez
Journal:  Nat Genet       Date:  2005-09-04       Impact factor: 38.330

5.  SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.

Authors:  Helen B Pearson; Pedro A Perez-Mancera; Lukas E Dow; Andrew Ryan; Pierre Tennstedt; Debora Bogani; Imogen Elsum; Andy Greenfield; David A Tuveson; Ronald Simon; Patrick O Humbert
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

6.  Error-prone polyploid mitosis during normal Drosophila development.

Authors:  Donald T Fox; Joseph G Gall; Allan C Spradling
Journal:  Genes Dev       Date:  2010-10-15       Impact factor: 11.361

7.  Therapeutic vaccination for cancer immunotherapy: antigen selection and clinical responses.

Authors:  Astrid Geldmacher; Anja Freier; Florian O Losch; Peter Walden
Journal:  Hum Vaccin       Date:  2011-01-01

8.  Alterations of the Notch pathway in lung cancer.

Authors:  Britta Westhoff; Ivan N Colaluca; Giovanni D'Ario; Maddalena Donzelli; Daniela Tosoni; Sara Volorio; Giuseppe Pelosi; Lorenzo Spaggiari; Giovanni Mazzarol; Giuseppe Viale; Salvatore Pece; Pier Paolo Di Fiore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

Review 9.  Notch inhibitors as a new tool in the war on cancer: a pathway to watch.

Authors:  Benjamin Purow
Journal:  Curr Pharm Biotechnol       Date:  2009-02       Impact factor: 2.837

Review 10.  Modeling tumor invasion and metastasis in Drosophila.

Authors:  Wayne O Miles; Nicholas J Dyson; James A Walker
Journal:  Dis Model Mech       Date:  2011-10-06       Impact factor: 5.758

View more
  118 in total

1.  Drak/STK17A Drives Neoplastic Glial Proliferation through Modulation of MRLC Signaling.

Authors:  Alexander S Chen; Joanna Wardwell-Ozgo; Nilang N Shah; Deidre Wright; Christina L Appin; Krishanthan Vigneswaran; Daniel J Brat; Harley I Kornblum; Renee D Read
Journal:  Cancer Res       Date:  2018-12-10       Impact factor: 12.701

Review 2.  Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.

Authors:  Maria Letizia Ciavatta; Florence Lefranc; Marianna Carbone; Ernesto Mollo; Margherita Gavagnin; Tania Betancourt; Ramesh Dasari; Alexander Kornienko; Robert Kiss
Journal:  Med Res Rev       Date:  2016-12-07       Impact factor: 12.944

3.  The SCFSlimb E3 ligase complex regulates asymmetric division to inhibit neuroblast overgrowth.

Authors:  Song Li; Cheng Wang; Edwin Sandanaraj; Sherry S Y Aw; Chwee T Koe; Jack J L Wong; Fengwei Yu; Beng T Ang; Carol Tang; Hongyan Wang
Journal:  EMBO Rep       Date:  2014-01-10       Impact factor: 8.807

Review 4.  Regulation of Carbohydrate Energy Metabolism in Drosophila melanogaster.

Authors:  Jaakko Mattila; Ville Hietakangas
Journal:  Genetics       Date:  2017-12       Impact factor: 4.562

5.  A Drosophila model to study retinitis pigmentosa pathology associated with mutations in the core splicing factor Prp8.

Authors:  Dimitrije Stanković; Ann-Katrin Claudius; Thomas Schertel; Tina Bresser; Mirka Uhlirova
Journal:  Dis Model Mech       Date:  2020-06-26       Impact factor: 5.758

6.  Regulation of Notch signaling and endocytosis by the Lgl neoplastic tumor suppressor.

Authors:  Marta Portela; Linda M Parsons; Nicola A Grzeschik; Helena E Richardson
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Malignant Drosophila tumors interrupt insulin signaling to induce cachexia-like wasting.

Authors:  Alejandra Figueroa-Clarevega; David Bilder
Journal:  Dev Cell       Date:  2015-04-06       Impact factor: 12.270

8.  Precision Oncology Framework for Investigation of Exercise As Treatment for Cancer.

Authors:  Lee W Jones
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544

9.  Induction and Diagnosis of Tumors in Drosophila Imaginal Disc Epithelia.

Authors:  Kenta Morimoto; Yoichiro Tamori
Journal:  J Vis Exp       Date:  2017-07-25       Impact factor: 1.355

Review 10.  The biology and mathematical modelling of glioma invasion: a review.

Authors:  J C L Alfonso; K Talkenberger; M Seifert; B Klink; A Hawkins-Daarud; K R Swanson; H Hatzikirou; A Deutsch
Journal:  J R Soc Interface       Date:  2017-11       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.